Background: Modern researches have focused the attention towards the potential advantage of chloroquine, a broadly used antimalarial drug, in the treatment of patients infected by the novel appeared coronavirus (SARS-CoV-2). Chloroquine/hydroxychloroquine has been frequently used in treating SARS-CoV-2 infection. Which is useful in controlling the cytokine storm that occurs late-phase in critically ill SARS-CoV-2 infected patients. The scientific community should consider this information in light of previous experiments with Chloroquine/hydroxychloroquine in the field of antiviral research. Methods: In the view of current situation efforts of international health professionals have since focused on rapid diagnosis and isolation of patients as well as the search for therapies able to counter the most severe effects of the disease. It is mandatory to investigate the possible effect of chloroquine/hydroxychloroquine against SARS-CoV-2. Since this molecule was previously described as a potent inhibitor of most coronaviruses, including SARS-CoV-1. Preliminary trials of chloroquine repurposing in the treatment of COVID-19 in China have been encouraging, leading to several new trials. Here we discuss the possible mechanisms of chloroquine interference with the SARS-CoV-2 replication cycle. Results: Chloroquine has been shown to be capable of inhibiting the in vitro replication of several coronaviruses. Recent publications support the hypothesis that chloroquine/hydroxychloroquine can improve the clinical outcome of patients infected by SARS-CoV-2.
Therapeutic Preferences for Coronavirus 2(SARS-CoV-2) Patients